A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Shanghai Henlius Biotech
Shanghai Henlius Biotech
UNC Lineberger Comprehensive Cancer Center
Grupo Español de Investigación en Cáncer de Ovario
National Cancer Institute (NCI)
ISA Associates, Inc.
Ohio State University Comprehensive Cancer Center
Regor Pharmaceuticals Inc.
Akdeniz University Hospital
Toros University
Marmara University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Seagen Inc.
Eli Lilly and Company
Pfizer
VCS Foundation
Institut Claudius Regaud
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Pittsburgh
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
Kathmandu University School of Medical Sciences
Genentech, Inc.
Evopoint Biosciences Inc.
UNC Lineberger Comprehensive Cancer Center
Yuzuncu Yil University
Seagen Inc.
Centre Hospitalier Intercommunal Creteil
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Eli Lilly and Company
OncoC4, Inc.
Kortuc, Inc.
Bayer
KaliVir Immunotherapeutics
Centre hospitalier de l'Université de Montréal (CHUM)
National Institutes of Health Clinical Center (CC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Eastern Cooperative Oncology Group
International Agency for Research on Cancer
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Institut Paoli-Calmettes
Imperial College London